SCHEMBL5225249

SCHEMBL5225249

CCCCn1c(-c2ccccc2)nc(-c2ccc(OC)cc2)c1CN(Cc1ccc(C(N)=O)c(CC(=O)O)c1)CC1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.38
HDAC1 Q13547 1/20 0.34
PTGDR2 Q9Y5Y4 2/20 0.33
SLC6A9 P48067 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
CRHBP P24387 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
CRHR2 Q13324 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
SLC6A5 Q9Y345 1/20 0.33
BCHE P06276 3/20 0.33
CNR2 P34972 1/20 0.32
GNRHR P30968 1/20 0.32
AVPR1B P47901 1/20 0.32
PARP1 P09874 1/20 0.32
PTGES O14684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648105 0.92 C5AR1 (0.38) C5AR1HDAC1SLC6A9MEN1ALDH1A1
SCHEMBL5633347 0.89 C5AR1 (0.40) C5AR1HDAC1PTGDR2MAPTCNR2
SCHEMBL648473 0.89 C5AR1 (0.37) C5AR1HDAC1SLC6A9MEN1ALDH1A1
SCHEMBL5633847 0.86 C5AR1 (0.53) C5AR1MEN1ALDH1A1LMNAMAPT
SCHEMBL1913025 0.86 C5AR1 (0.41) C5AR1HDAC1ALDH1A1LMNABCHE
SCHEMBL5218869 0.86 C5AR1 (0.37) C5AR1HDAC1PTGDR2BCHECNR2
SCHEMBL651698 0.86 NPC1 (0.36) MEN1ALDH1A1LMNAMAPTCRHBP
SCHEMBL5137557 0.85 C5AR1 (0.42) C5AR1SLC6A9MEN1ALDH1A1LMNA
SCHEMBL650630 0.85 MKNK1 (0.36) MEN1ALDH1A1LMNAMAPTCRHBP
SCHEMBL648650 0.84 PDK1 (0.35) SLC6A9ALDH1A1MAPTHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed